Pharmacokinetics and Safety of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults. Randomized, Open-label, Single-dose, Cross-over, Phase 1 Study
Latest Information Update: 10 Apr 2023
At a glance
- Drugs BPS 034 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Hyundai Pharmaceutical
Most Recent Events
- 10 Apr 2023 New trial record